The pathogenesis of osteoarthritis involves bone, cartilage and synovial inflammation: May estrogen be a magic bullet?

Menopause International

Volumn 18, Issue 4, 2012, Pages 139-146

  Karsdal, M A ^a   Bay Jensen, A C ^a   Henriksen, K ^a   Christiansen, C ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

Bone; Cartilage; CTX I; CTX II; Metabolic OA; Osteoarthritis; Turnover

Indexed keywords

BAZEDOXIFENE; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CATHEPSIN K INHIBITOR; CENTCHROMAN; COLLAGEN TYPE 1; COLLAGEN TYPE 2; CONJUGATED ESTROGEN; ESTROGEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LASOFOXIFENE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TIBOLONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTHRITIS; BONE DEFECT; BONE DENSITY; BONE TURNOVER; CARTILAGE CELL; CARTILAGE DEGENERATION; CHONDROPROTECTION; DISEASE SEVERITY; DRUG EFFECT; DRUG MEGADOSE; ESTROGEN THERAPY; FEMALE; HOMEOSTASIS; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; JOINT PROSTHESIS; LOW DRUG DOSE; NONHUMAN; OSTEOARTHRITIS; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPHYTE; OSTEOSCLEROSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PLEIOTROPY; POSTMENOPAUSE; REVIEW; RHEUMATOID ARTHRITIS; SYNOVITIS; TREATMENT WITHDRAWAL;

BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CARTILAGE; CHONDROCYTES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HOMEOSTASIS; HUMANS; MENOPAUSE; OSTEOARTHRITIS; OSTEOBLASTS; OSTEOCLASTS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SYNOVITIS;

EID: 84872516767     PISSN: 17540453     EISSN: 17540461     Source Type: Journal    
DOI: 10.1258/mi.2012.012025     Document Type: Review

References (132)

1. Abramson SB, Attur M, Yazici Y. Prospects for disease modification in osteoarthritis. Nat Clin Pract Rheumatol 2006;2:304-12
2. Felson DT, Neogi T. Osteoarthritis: is it a disease of cartilage or of bone? Arthritis Rheum 2004;50:341-4
3. Hayami T, Pickarski M, Wesolowski GA, et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 2004;50:1193-206
4. Mansell JP, Collins C, Bailey AJ. Bone, not cartilage, should be the major focus in osteoarthritis. Nat Clin Pract Rheumatol 2007;3:306-7
5. Mansell JP, Bailey AJ. Abnormal cancellous bone collagen metabolism in osteoarthritis. J Clin Invest 1998; 101:1596-603
6. Bailey AJ, Mansell JP. Do subchondral bone changes exacerbate or precede articular cartilage destruction in osteoarthritis of the elderly? Gerontology 1997;43:296-304
7. Gineyts E, Mo JA, Ko A, et al. Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis. Ann Rheum Dis 2004;63:857-61
8. Manicourt DH, Altman RD, Williams JM, et al. Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. Arthritis Rheum 1999;42:1159-67
9. Bay-Jensen AC, Hoegh-Madsen S, Dam E, et al. Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis? Rheumatol Int 2010;30:435-42
10. Karsdal MA, Madsen SH, Christiansen C, et al. Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther 2008;10:R63. Epub 30 May 2008
11. Carbone LD, Nevitt MC, Wildy K, et al. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum 2004;50:3516-25
12. Felson DT, Nevitt MC. The effects of estrogen on osteoarthritis. Curr Opin Rheumatol 1998;10:269-72
13. Oliveria SA, Felson DT, Klein RA, Reed JI, Walker AM. Estrogen replacement therapy and the development of osteoarthritis. Epidemiology 1996;7:415-9
14. Kellgren JH, Moore R. Generalized osteoarthritis and Heberden's nodes. Br Med J 1952;1:181-7
15. Sondergaard BC, Ostergaard S, Christiansen C, Tankó LB, Karsdal MA. The effect of oral calcitonin on cartilage turnover and surface erosion in the ovariectomized rat model I. Arthritis Rheum 2007;56:2674-8
16. Cauley JA, Kwoh CK, Egeland G, et al. Serum sex hormones and severity of osteoarthritis of the hand. J Rheumatol 1993;20:1170-5
17. Spector TD, Perry LA, Jubb RW. Endogenous sex steroid levels in women with generalised osteoarthritis. Clin Rheumatol 1991;10:316-9
18. Sowers MR, McConnell D, Jannausch M, Buyuktur AG, Hochberg M, Jamadar DA. Estradiol and its metabolites and their association with knee osteoarthritis. Arthritis Rheum 2006;54:2481-7
19. Felson DT, Zhang Y, Hannan MT, et al. The incidence and natural history of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum 1995;38:1500-5
20. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99
21. Ham KD, Loeser RF, Lindgren BR, Carlson CS. Effects of long-term estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys. Arthritis Rheum 2002;46:1956-64
22. Oestergaard S, Sondergaard BC, Hoegh-Andersen P, et al. Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. Arthritis Rheum 2006;54:2441-51
23. Christgau S, Tanko LB, Cloos PA, et al. Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause 2004;11:508-18
24. Mouritzen U, Christgau S, Lehmann HJ, Tanko LB, Christiansen C. Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis 2003;62:332-6
25. Schaller S, Henriksen K, Hoegh-Andersen P, et al. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol 2005;3:553-80
26. Schaller S, Henriksen K, Sveigaard C, et al. The chloride channel inhibitor n53736 prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 2004;19:1144-53
27. Ravn P, Hosking D, Thompson D, et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 1999;84:2363-8
28. Sondergaard BC, Henriksen K, Wulf H, et al. Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthritis Cartilage 2006;14:738-48
29. Nielsen Rh, Stoop R, Leeming DJ, et al. Evaluation of cartilage damage by measuring collagen degradation products in joint extracts in a traumatic model of osteoarthritis. Biomarkers 2008;13:79-87
30. Reijman M, Hazes JM, Bierma-Zeinstra SM, et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 2004;50:2471-8
31. Ham KD, Carlson CS. Effects of estrogen replacement therapy on bone turnover in subchondral bone and epiphyseal metaphyseal cancellous bone of ovariectomized cynomolgus monkeys. J Bone Miner Res 2004;19:823-9
32. Hayami T, Pickarski M, Zhuo Y, Wesolowski GA, Rodan GA, Duong LT. Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. Bone 2006;38:234-43
33. Garnero P, Peterfy C, Zaim S, Schoenharting M. Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study. Arthritis Rheum 2005;52:2822-9
34. Hunter DJ, Hart D, Snieder H, Bettica P, Swaminathan R, Spector TD. Evidence of altered bone turnover, vitamin D and calcium regulation with knee osteoarthritis in female twins. Rheumatology (Oxford) 2003;42:1311-6
35. Hunter DJ, Spector TD. The role of bone metabolism in osteoarthritis. Curr Rheumatol Rep 2003;5:15-9
36. Dieppe P, Cushnaghan J, Young P, Kirwan J. Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann Rheum Dis 1993;52:557-63
37. Arden N, Nevitt MC. Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol 2006;20:3-25
38. Calvo E, Castaneda S, Largo R, Fernandez-Valle ME, Rodriguez-Salvanes F, Herrero-Beaumont G. Osteoporosis increases the severity of cartilage damage in an experimental model of osteoarthritis in rabbits. Osteoarthritis Cartilage 2007;15:69-77
39. Ma HL, Blanchet TJ, Peluso D, Hopkins B, Morris EA, Glasson SS. Osteoarthritis severity is sex dependent in a surgical mouse model. Osteoarthritis Cartilage 2007;15:695-700
40. Hoegh-Andersen P, Tanko LB, Andersen TL, et al. Ovariectomized rats as a model of postmenopausal osteoarthritis: validation and application. Arthritis Res Ther 2004;6:R169-80
41. Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 2010;25:937-47
42. Connor JR, LePage C, Swift BA, et al. Protective effects of a cathepsin K inhibitor, SB-553484, in the canine partial medial meniscectomy model of osteoarthritis. Osteoarthritis Cartilage 2009;17:1236-43
43. Hayami T, Zhuo Y, Wesolowski GA, Pickarski M, Duong LT. Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis. Bone 2012;50:1250-9
44. Behets C, Williams JM, Chappard D, Devogelaer JP, Manicourt DH. Effects of calcitonin on subchondral trabecular bone changes and on osteoarthritic cartilage lesions after acute anterior cruciate ligament deficiency. J Bone Miner Res 2004;19:1821-6
45. Karsdal MA, Tanko LB, Riis BJ, et al. Calcitonin is involved in cartilage homeostasis: is calcitonin a treatment for OA? Osteoarthritis Cartilage 2006;14:617-24
46. Wronski TJ, Yen CF, Burton KW, et al. Skeletal effects of calcitonin in ovariectomized rats. Endocrinology 1991;129:2246-50
47. Martin TJ, Harris GS, Melick RA, Fraser JR. Effect of calcitonin on glycosaminoglycan synthesis by embryo calf bone cells in vitro. Experientia 1969;25:375-6
48. Baxter E, Fraser JR, Harris GS, Martin TJ, Melick RA. Stimulation of glycosaminoglycan synthesis by thyrocalcitonin preparations. Med J Aust 1968;1:216-7
49. Hellio MP, Peschard MJ, Cohen C, Richard M, Vignon E. Calcitonin inhibits phospholipase A2 and collagenase activity of human osteoarthritic chondrocytes. Osteoarthritis Cartilage 1997;5:121-8
50. Franchimont P, Bassleer C, Henrotin Y, Gysen P, Bassleer R. Effects of human and salmon calcitonin on human articular chondrocytes cultivated in clusters. J Clin Endocrinol Metab 1989;69:259-66
51. Manicourt DH, Devogelaer JP, Azria M, Silverman S. Rationale for the potential use of calcitonin in osteoarthritis. J Musculoskelet Neuronal Interact 2005;5:285-93
52. Bagger YZ, Tanko LB, Alexandersen P, et al. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone 2005;37:425-30
53. Khaldi L, Karachalios T, Galanos A, Lyritis GP. Morphometric changes in the epiphyseal plate of the growing and young adult male rat after long-term salmon calcitonin administration. Calcif Tissue Int 2005;76:426-32
54. El Hajjaji H, Williams JM, Devogelaer JP, Lenz ME, Thonar EJ, Manicourt DH. Treatment with calcitonin prevents the net loss of collagen, hyaluronan and proteoglycan aggregates from cartilage in the early stages of canine experimental osteoarthritis. Osteoarthritis Cartilage 2004;12:904-11
55. Manicourt DH, Azria M, Mindeholm L, Thonar EJ, Devogelaer JP. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum 2006;54:3205-11
56. Karsdal MA, Byrjalsen I, Henriksen K, et al. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study. Osteoarthritis Cartilage 2010;18:150-9
57. Karsdal MA, Byrjalsen I, Henriksen K, Riis BJ, Christiansen C. A pharmacokinetic and pharmacodynamic comparison of synthetic and recombinant oral salmon calcitonin. J Clin Pharmacol 2009;49:229-34
58. Karsdal MA, Sondergaard BC, Arnold M, Christiansen C. Calcitonin affects both bone and cartilage: a dual action treatment for osteoarthritis? Ann N Y Acad Sci 2007;1117:181-95
59. Karsdal MA, Leeming DJ, Byrjalsen I, Christiansen C. Tibolone inhibits bone resorption without secondary positive effects on cartilage degradation. BMC Musculoskelet Disord 2008;9:153
60. Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 2006;354:2250-61
61. Vasikaran S, Eastell R, Bruyere O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011;22:391-420
62. Pereda CA, Hannon RA, Naylor KE, Eastell R. The impact of subcutaneous oestradiol implants on biochemical markers of bone turnover and bone mineral density in postmenopausal women. Br J Obstet Gynaecol 2002;109:812-20
63. Prestwood KM, Gunness M, Muchmore DB, Lu Y,Wong M, Raisz LG. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 2000;85:2197-202
64. Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-76
65. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68
66. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45
67. Eastell R, Reid DM, Vukicevic S, et al. Effects of 3years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis. Bone 2012;50:1135-40
68. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008;23:525-35
69. Sorensen MG, Henriksen K, Dziegiel MH, Tanko LB, Karsdal MA. Estrogen directly attenuates human osteoclastogenesis, but has no effect on resorption by mature osteoclasts. DNA Cell Biol 2006;25:475-83
70. Richette P, Corvol M, Bardin T. Estrogens, cartilage, and osteoarthritis. Joint Bone Spine 2003;70:257-62
71. Dayani N, Corvol MT, Robel P, et al. Estrogen receptors in cultured rabbit articular chondrocytes: influence of age. J Steroid Biochem 1988;31:351-6
72. Claassen H, Hassenpflug J, Schunke M, Sierralta W, Thole H, Kurz B. Immunohistochemical detection of estrogen receptor alpha in articular chondrocytes from cows, pigs and humans: in situ and in vitro results. Ann Anat 2001;183:223-7
73. Ushiyama T, Ueyama H, Inoue K, Ohkubo I, Hukuda S. Expression of genes for estrogen receptors alpha and beta in human articular chondrocytes. Osteoarthritis Cartilage 1999;7:560-6
74. Richmond RS, Carlson CS, Register TC, Shanker G, Loeser RF. Functional estrogen receptors in adult articular cartilage: estrogen replacement therapy increases chondrocyte synthesis of proteoglycans and insulin-like growth factor binding protein 2. Arthritis Rheum 2000;43:2081-90
75. Christiansen C, Tanko LB, Warming L, et al. Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate. Osteoporos Int 2003;14:609-13
76. Lehmann HJ, Mouritzen U, Christgau S, Cloos PA, Christiansen C. Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann Rheum Dis 2001;61:530-3
77. Cirillo DJ, Wallace RB, Wu L, Yood RA. Effect of hormone therapy on risk of hip and knee joint replacement in the Women's Health Initiative. Arthritis Rheum 2006;54:3194-204
78. Oliveria SA, Felson DT, Reed JI, Cirillo PA, Walker AM. Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization. Arthritis Rheum 1995;38:1134-41
79. Kerin A, Patwari P, Kuettner K, Cole A, Grodzinsky A. Molecular basis of osteoarthritis: biomechanical aspects. Cell Mol Life Sci 2002;59:27-35
80. Pampena DA, Robertson KA, Litvinova O, Lajoie G, Goldberg HA, Hunter GK. Inhibition of hydroxyapatite formation by osteopontin phosphopeptides. Biochem J 2004;378:1083-7
81. Tanko LB, Sondergaard BC, Oestergaard S, Karsdal MA, Christiansen C. An update review of cellular mechanisms conferring the indirect and direct effects of estrogen on articular cartilage. Climacteric 2008;11:4-16
82. Richette P, Dumontier MF, Francois M, et al. Dual effects of 17beta-oestradiol on interleukin 1beta-induced proteoglycan degradation in chondrocytes. Ann Rheum Dis 2004;63:191-9
83. Tinti L, Niccolini S, Lamboglia A, Pascarelli NA, Cervone R, Fioravanti A. Raloxifene protects cultured human chondrocytes from IL-1beta induced damage: a biochemical and morphological study. Eur J Pharmacol 2011;670:67-73
84. Hattori Y, Kojima T, Kato D, Matsubara H, Takigawa M, Ishiguro N. A selective estrogen receptor modulator inhibits tumor necrosis factor-alpha-induced apoptosis through the ERK1/2 signaling pathway in human chondrocytes. Biochem Biophys Res Commun 2012;421:418-24
85. Lee YJ, Lee EB, Kwon YE, et al. Effect of estrogen on the expression of matrix metalloproteinase (MMP)-1, MMP-3, and MMP-13 and tissue inhibitor of metalloproternase-1 in osteoarthritis chondrocytes. Rheumatol Int 2003;23:282-8
86. Song YJ, Wu ZH, Lin SQ, Weng XS, Qiu GX. [The effect of estrogen and progestin on the expression of matrix metalloproteinases, tissue inhibitor of metalloproteinase and interleukin-1beta mRNA in synovia of OA rabbit model]. Zhonghua Yi Xue Za Zhi 2003;83:498-503
87. Claassen H, Steffen R, Hassenpflug J, et al. 17beta-estradiol reduces expression of MMP-1, -3, and -13 in human primary articular chondrocytes from female patients cultured in a three dimensional alginate system. Cell Tissue Res 2010;342:283-93
88. Cheng P, Ma X, Xue Y, Li S, Zhang Z. Effects of estradiol on proliferation and metabolism of rabbit mandibular condylar cartilage cells in vitro. Chin Med J (Engl) 2003;116:1413-7
89. Saggese G, Federico G, Cinquanta L. In vitro effects of growth hormone and other hormones on chondrocytes and osteoblast-like cells. Acta Paediatr Suppl 1993;82(Suppl. 391):54-9
90. Srivastava S, Toraldo G, Weitzmann MN, Cenci S, Ross FP, Pacifici R. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J Biol Chem 2001;276:8836-40
91. Shevde NK, Bendixen AC, Dienger KM, Pike JW. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA 2000;97:7829-34
92. Oursler MJ, Osdoby P, Pyfferoen J, Riggs BL, Spelsberg TC. Avian osteoclasts as estrogen target cells. Proc Natl Acad Sci USA 1991;88:6613-7
93. Oursler MJ, Pederson L, Fitzpatrick L, Riggs BL, Spelsberg T. Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. Proc Natl Acad Sci USA 1994;91:5227-31
94. Oursler MJ, Pederson L, Pyfferoen J, Osdoby P, Fitzpatrick L, Spelsberg TC. Estrogen modulation of avian osteoclast lysosomal gene expression. Endocrinology 1993;132:1373-80
95. Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996;273:1236-8
96. Gowen M, Lazner F, Dodds R, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 1999;14:1654-63
97. Hollberg K, Hultenby K, Hayman A, Cox T, Andersson G. Osteoclasts from mice deficient in tartrate-resistant acid phosphatase have altered ruffled borders and disturbed intracellular vesicular transport. Exp Cell Res 2002;279:227-38
98. Parikka V, Lehenkari P, Sassi ML, et al. Estrogen reduces the depth of resorption pits by disturbing the organic bone matrix degradation activity of mature osteoclasts. Endocrinology 2001;142:5371-8
99. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003;111:1221-30
100. Khosla S, Atkinson EJ, Dunstan CR, O'Fallon WM. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 2002;87:1550-4
101. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004;292:490-5
102. Saika M, Inoue D, Kido S, Matsumoto T. 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology 2001;142:2205-12
103. Bord S, Ireland DC, Beavan SR, Compston JE. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 2003;32:136-41
104. Michael H, Harkonen PL, Kangas L, Vaananen HK, Hentunen TA. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro. Br J Pharmacol 2007;151:384-95
105. Riggs BL, Khosla S, Melton LJ III. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002;23:279-302
106. Kimble RB, Srivastava S, Ross FP, Matayoshi A, Pacifici R. Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. J Biol Chem 1996;271:28890-97
107. Cenci S, Weitzmann MN, Roggia C, et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 2000;106:1229-37
108. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000;21:115-37
109. Goldring MB, Marcu KB. Cartilage homeostasis in health and rheumatic diseases. Arthritis Res Ther 2009;11:224
110. Grall F, Gu X, Tan L, et al. Responses to the proinflammatory cytokines interleukin-1 and tumour necrosis factor alpha in cells derived from rheumatoid synovium and other joint tissues involve nuclear factor kappaB-mediated induction of the Ets transcription factor ESE-1. Arthritis Rheum 2003;48:1249-60
111. Goldring SR, Goldring MB. The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin Orthop Relat Res 2004;427(Suppl):S27-36
112. Cutolo M, Sulli A, Straub RH. Estrogen metabolism and autoimmunity. Autoimmun Rev 2012;11:A460-4
113. Islander U, Jochems C, Lagerquist MK, Forsblad-d'Elia H, Carlsten H. Estrogens in rheumatoid arthritis; the immune system and bone. Mol Cell Endocrinol 2011;335:14-29
114. Islander U, Jochems C, Stubelius A, et al. Combined treatment with dexamethasone and raloxifene totally abrogates osteoporosis and joint destruction in experimental postmenopausal arthritis. Arthritis Res Ther 2011;13:R96
115. Dulos J, Vijn P, van DC, et al. Suppression of the inflammatory response in experimental arthritis is mediated via estrogen receptor alpha but not estrogen receptor beta. Arthritis Res Ther 2010;12:R101
116. Yang YH, Ngo D, Jones M, Simpson E, Fritzemeier KH, Morand EF. Endogenous estrogen regulation of inflammatory arthritis and cytokine expression in male mice, predominantly via estrogen receptor alpha. Arthritis Rheum 2010;62:1017-25
117. Nielsen Rh, Christiansen C, Stolina M, Karsdal MA. Oestrogen exhibits type II collagen protective effects and attenuates collagen-induced arthritis in rats. Clin Exp Immunol 2008;152:21-7
118. Jochems C, Lagerquist M, Hakansson C, Ohlsson C, Carlsten H. Long-term antiarthritic and anti-osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis. Clin Exp Immunol 2008;152:593-7
119. Yoshioka T, Hagino H, Yamasaki D, Okano T, Teshima R. Effect of estrogen replacement therapy on arthritis and bone mineral density in estrogen-replete rats with collagen-induced arthritis. Mod Rheumatol 2008;18:23-8
120. Yamasaki D, Enokida M, Okano T, Hagino H, Teshima R. Effects of ovariectomy and estrogen replacement therapy on arthritis and bone mineral density in rats with collagen-induced arthritis. Bone 2001;28:634-40
121. Ganesan K, Balachandran C, Manohar BM, Puvanakrishnan R. Comparative studies on the interplay of testosterone, estrogen and progesterone in collagen induced arthritis in rats. Bone 2008;43:758-65
122. Schmidt M, Naumann H, Weidler C, Schellenberg M, Anders S, Straub RH. Inflammation and sex hormone metabolism. Ann N Y Acad Sci 2006;1069:236-46
123. Carlsten H. Immune responses and bone loss: the estrogen connection. Immunol Rev 2005;208:194-206
124. Jochems C, Islander U, Erlandsson M, Verdrengh M, Ohlsson C, Carlsten H. Osteoporosis in experimental postmenopausal polyarthritis: the relative contributions of estrogen deficiency and inflammation. Arthritis Res Ther 2005;7:R837-43
125. Harle P, Bongartz T, Scholmerich J, Muller-Ladner U, Straub RH. Predictive and potentially predictive factors in early arthritis: a multidisciplinary approach. Rheumatology (Oxford) 2005;44:426-33
126. Ishizuka M, Hatori M, Suzuki T, et al. Sex steroid receptors in rheumatoid arthritis. Clin Sci (Lond) 2004;106:293-300
127. Schett G, Smolen JS. New insights in the mechanism of bone loss in arthritis. Curr Pharm Des 2005;11:3039-49
128. Schett G. Erosive arthritis. Arthritis Res Ther 2007;9(Suppl. 1):S2
129. Schett G. Osteoimmunology in rheumatic diseases. Arthritis Res Ther 2009;11:210
130. Landewe R. Predictive markers in rapidly progressing rheumatoid arthritis. J Rheumatol Suppl 2007;80:8-15
131. Syversen SW, Goll GL, van der HD, et al. Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression. J Rheumatol 2009;36:266-72
132. Syversen SW, Goll GL, van der HD, et al. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. Ann Rheum Dis 2010;69:345-51